Table 1.

Potential cost savings each year according to the number of patients started on anti-TNF-α therapy that year.

YearNo. Patients Newly Starting Anti-TNF-α Who Never Tried SC MTXAverage Cost of A Year of Treatment For The New Anti-TNF-α Patients*, £No. Patients Who Could Have Been Successful Using SC MTX**Potential Saving that Year, £
200112130,130650,203.92
200216167,310866,938.56
200323223,0801192,040.52
200413130,130650,203.92
200517158,015866,938.56
200618185,900975,305.88
200719185,900975,305.88
200828306,73514117,142.48
200939418,27519158,979.08
201047474,04523192,448.36

  • ↵* Based on the 2010 price (£) for normal weekly dosage of 50 mg etanercept for 52 weeks.

  • ↵** Based on 49% success rate. SC: subcutaneous.